# SBRT Followed by Ipilimumab N01, Sintilimab, Nab-Paclitaxel and Gemcitabine for Locally Advanced Pancreatic Cancer

> **NCT07683221** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Shandong Cancer Hospital and Institute** · enrollment: 47 (estimated)

## Conditions studied

- Pancreatic Cancer

## Interventions

- **DRUG:** SBRT + Ipilimumab N01 + Sintilimab + AG Chemotherapy

## Key facts

- **NCT ID:** NCT07683221
- **Lead sponsor:** Shandong Cancer Hospital and Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-07-15
- **Primary completion:** 2029-07-15
- **Final completion:** 2029-07-15
- **Target enrollment:** 47 (ESTIMATED)
- **Last updated:** 2026-07-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07683221

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07683221, "SBRT Followed by Ipilimumab N01, Sintilimab, Nab-Paclitaxel and Gemcitabine for Locally Advanced Pancreatic Cancer". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07683221. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*